Manager TitleAgeSince
President - 2023-12-13
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 2023-12-13
Director/Board Member - 2023-12-13
Date Insider Type Main position Quantity % Market Cap.
12/14/23 Issuer sale

Director

127,934 0.0678%
12/14/23 Issuer sale

Chief Executive Officer

643,595 0.3411%
12/14/23 Issuer sale

Director

97,934 0.0519%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
+1.14%+3.46%+4.57%+24.14% 50.5B
-1.36%+3.15%+479.46%+614.84% 46.01B
-2.04%+2.82%+18.13%+91.23% 42.85B
+2.72%+5.93%+33.12%+19.66% 41.03B
0.00%-3.91%+17.87%+47.98% 32.02B
+0.72%+2.62%+32.57%+145.37% 16.98B
-1.85%-0.25% - - 17.05B
+3.06%+4.63%+7.40%+35.00% 14.3B
+0.50%+2.49%+83.90%+46.53% 13.84B
Average +0.28%+2.01%+84.63%+128.09% 30.51B
Weighted average by Cap. +0.15%+2.37%+104.14%+152.88%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock